Das Tumorsuppressorgen p53: Die theoretischen Grundlagen und ihre Bedeutung für die Pathologie

Pathologe

Volumn 17, Issue 3, 1996, Pages 181-188

  Poremba, C ^a   Bankfalvi, A ^a   Dockhorn Dworniczak, B ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MELANOMA; MOLECULAR BIOLOGY; REVIEW; SKIN CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; HUMANS; MUTATION; NEOPLASMS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029949345     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002920050153     Document Type: Article

References (62)

1. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer [see comments]. J Natl Cancer Inst 85: 200-206
2. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540-548
3. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene. J Pathol 172: 5-12
4. Bankfalvi A. Navabi H, Bier B, Böcker W, Jasani B, Schmid KW (1994) Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 174: 223-228
5. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C (1993) A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when genertated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7: 2565-2574
6. Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa [see comments]. Nature 350: 429-431
7. Caron-de-Fromentel C. Soussi T (1992) TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 4: 1-15
8. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355
9. Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547-556
10. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356
11. Dockhorn-Dworniczak B, Dworniczak B, Brömmelkamp L, Bulles J, Horst J, Böcker WW (1991) Non-isotopic detection of single strand conformation polymorphism (PCR-SSCP): a rapid and sensitive technique in diagnosis of phenylketonuria. Nucl Acids Res 19: 2500
12. Dockhorn-Dworniczak B, Poremba C, Dantcheva R, Stücker A, Brömmelkamp E, Blasius S, Mellin W, Roessner A, Yandell DW, Böcker W (1994) Rapid detection of loss of heterozygosity of chromosome 17p by polymerase chain reaction-based variable number of tandem repeat analysis and detection of single-strand conformation polymorphism of intragenic p53 polymorphisms. Virchows Arch 424: 337-342
13. Drobetsky EA, Grosovsky AJ, Glickman BW (1987) The specificity of UV-induced mutations at an endogenous locus in mamallian cells. Proc Natl Acad Sci USA 84: 90103
14. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
15. Fearon ER (1992) Genetic alterations underlying colorectal tumorigenesis. Cancer Surv 12: 119-136
16. Fields S, Jang SK (1990) Presence of a potent transcription activating sequence in the p53. Science 249: 1046-1049
17. Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602
18. Harris CC (1993) p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1981
19. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene [see comments]. N Engl J Med 329: 1318-1327
20. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828
21. Hayashi K, Yandell DW (1993) How sensitive is PCR-SSCP? Hum Mut 2: 338-346
22. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
23. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas [see comments]. Nature 350: 427-428
24. Hunter T (1993) Breaking the cycle. Cell 75: 839-841
25. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875-886
26. Hurlimann J (1993) Prognostic value of p53 protein expression in breast carcinomas. Pathol Res Pract 189: 996-1003
27. Imamura J, Miyoshi I, Koeffler HP (1994) p53 in hematologic malignancies. Blood 84: 2412-2421
28. Kastan MB, Onyekwere O, Sidransky B, Vogelstein B. Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
29. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJJ (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597
30. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF (1992) p53 overexpression in formalin-fixed, paraffin-embedded tissue detected. J Histochem Cytochem 40: 1047-1051
31. Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914-10921
32. Lambkin HA, Mothersill CM, Kelehan P (1994) Variations in immunohistochemical detection of p53 protein overexpression. J Pathol 172: 13-18
33. Lane DP (1992) Cancer. p53, guardian of the genome [news; comment]. Nature 358: 15-16
34. Lane DP, Crawford LV (1979) Tantigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263
35. Levine AJ, Momand J (1990) Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes. Biochim Biophys Acta 1032: 119-136
36. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D (1994) The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409-416
37. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
38. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S (1985) Rearrangements of the cellular p53 gene in erythroleukaemic cells. Nature 314: 633-636
39. Munroe DG, Peacock JW, Benchimol S (1990) Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol 10: 3307-3313
40. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR (1992) DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89: 3030-3034
41. O'Rourke RW, Miller CW, Kato GJ, Simon KJ, Chen DL, Dang CV, Koeffler HP (1990) A potential transcriptional activation element in the p53 protein. Oncogene 5: 1829-1832
42. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M, Syrjänen K (1995) Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177: 225-232
43. Poremba C, Yandell DW, Huang Q, Little JB, Mellin W, Schmid KW, Böcker W, Dockhorn-Dworniczak B (1995) Frequency and spectrum of p53 mutations in gastric cancer - a molecular genetic and immunohistochemical study. Virchows Arch 426: 447-455
44. Poremba C, Yandell DW, Mellin W, Schimd KW, Reers B, Böcker W, Dockhorn-Dworniczak B (1995) Adenocarcinoma of the cardia in a young man: detection of somatic p53 mutation by immunohistochemistry and automated direct sequencing. Pathol Res Pract 191: 1004-1009
45. Poremba C, Yandell DW, Metze D, Kamanabrou D, Böcker W, Dockhorn-Dworniczak B (1995) Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 7: 331-339
46. Prives C (1994) How loops, beta sheets, and alpha helices help us to understand p53. Cell 78: 543-546
47. Sarnow P, Ho YS, Williams J, Levine AJ (1982) Adenovirus E1b-58kd tumor antigen and SV40 targe tumor antigen are physicatly associated with the same 54kd cellular protein in transformed cells. Cell 28: 387-394
48. Sato T, Hanada M, Bodrag S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG et al (1994) Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91: 9238-9242
49. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
50. Scholz RB, Milde-Langosch K, Jung R, Schlechte H, Kabisch H, Wagener C, Löning T (1993) Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: a comparison with SSCP analysis. Hum Mol Genet 2: 2155-2158
51. Shaulsky G, Ben-Ze'ev A, Rotter V (1990) Subcellular distribution of the p53 protein during the cell cycle. Oncogene 5: 1707-1711
52. Soussi T, Caron-de-Fromeutel C, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952
53. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL (1991) Expression of mutant p53 in melanoma. Cancer Res 51: 5976-5979
54. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG (1993) EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the, Proc Natl Acad Sci USA 90: 5455-5459
55. Terada T, Shimizu K, Izumi R, Nakanuma Y (1994) Methods in pathology. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiosarcoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 7: 249-252
56. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855
57. Wang Y, Reed M, Wang P, Stenger JE, Mayr G, Andersen ME, Schwedes JF, Tegtmeyer P (1993) p53 domains: identification and characterization of two autonomous DNA-binding sites. Genes Dev 7: 2575-2586
58. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases [see comments]. Nature 366: 701-704
59. Yamamoto M, Takahashi H (1993) Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch [A] 422: 127-132
60. Yandell DW, Campbell TA, Dayton SH, Petersen R, Walton D, Little JB, McKonckie-Rossell A, Buckley EG, Dryja TP (1989) Identification of cancer-causing point mutations in the human retinoblastoma gene and application to genetic counseling. N Engl J Med 321: 1689-1695
61. Yin XM, Oltval ZN, Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-323
62. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J (1994) Sunburn and p53 in the onset of skin cancer [see comments]. Nature 372: 773-776